↓ Skip to main content

Clinically Approved Antiviral Drug in an Orally Administrable Nanoparticle for COVID-19

Overview of attention for article published in ACS Pharmacology & Translational Science, December 2020
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#42 of 321)
  • High Attention Score compared to outputs of the same age (90th percentile)
  • Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

twitter
34 tweeters
reddit
2 Redditors

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
42 Mendeley
Title
Clinically Approved Antiviral Drug in an Orally Administrable Nanoparticle for COVID-19
Published in
ACS Pharmacology & Translational Science, December 2020
DOI 10.1021/acsptsci.0c00179
Pubmed ID
Authors

Bapurao Surnar, Mohammad Z. Kamran, Anuj S. Shah, Shanta Dhar

Abstract

There is urgent therapeutic need for COVID-19, a disease for which there are currently no widely effective approved treatments and the emergency use authorized drugs do not result in significant and widespread patient improvement. The food and drug administration-approved drug ivermectin has long been shown to be both antihelmintic agent and a potent inhibitor of viruses such as Yellow Fever Virus. In this study, we highlight the potential of ivermectin packaged in an orally administrable nanoparticle that could serve as a vehicle to deliver a more potent therapeutic antiviral dose and demonstrate its efficacy to decrease expression of viral spike protein and its receptor angiotensin-converting enzyme 2 (ACE2), both of which are keys to lowering disease transmission rates. We also report that the targeted nanoparticle delivered ivermectin is able to inhibit the nuclear transport activities mediated through proteins such as importin α/β1 heterodimer as a possible mechanism of action. This study sheds light on ivermectin-loaded, orally administrable, biodegradable nanoparticles to be a potential treatment option for the novel coronavirus through a multilevel inhibition. As both ACE2 targeting and the presence of spike protein are features shared among this class of virus, this platform technology has the potential to serve as a therapeutic tool not only for COVID-19 but for other coronavirus strains as well.

Twitter Demographics

The data shown below were collected from the profiles of 34 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 42 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 42 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 8 19%
Student > Ph. D. Student 4 10%
Researcher 4 10%
Other 3 7%
Professor > Associate Professor 2 5%
Other 10 24%
Unknown 11 26%
Readers by discipline Count As %
Medicine and Dentistry 10 24%
Pharmacology, Toxicology and Pharmaceutical Science 4 10%
Biochemistry, Genetics and Molecular Biology 3 7%
Chemistry 3 7%
Chemical Engineering 2 5%
Other 8 19%
Unknown 12 29%

Attention Score in Context

This research output has an Altmetric Attention Score of 22. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 July 2021.
All research outputs
#1,138,717
of 18,432,973 outputs
Outputs from ACS Pharmacology & Translational Science
#42
of 321 outputs
Outputs of similar age
#41,928
of 430,939 outputs
Outputs of similar age from ACS Pharmacology & Translational Science
#9
of 36 outputs
Altmetric has tracked 18,432,973 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 321 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.5. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 430,939 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 36 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 77% of its contemporaries.